NASDAQ$PRLD
Prelude Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Prelude Therapeutics reported Q2 2026 revenue of $5.7 million from its Incyte collaboration and a net loss of $13.9 million.
Prelude Therapeutics Inc. recognized $5.7 million in collaboration revenue during the second quarter of 2026 while advancing its JAK2 V617F and KAT6A programs. Operating expenses declined to $21.2 million from $32.2 million a year earlier due to paused SMARCA2 trials and workforce reductions. The company ended the quarter with $155.2 million in cash, cash equivalents, restricted cash and marketable securities, providing runway for at least twelve months.
- Q2 revenue of $5.7 million from Incyte Option Agreement; no product sales.
- Net loss narrowed to $13.9 million ($0.14 per share) from $31.2 million ($0.41 per share) in Q2 2025.
- R&D expenses fell 37% to $16.1 million as SMARCA2 programs were paused.
- Cash position of $155.2 million supports operations for at least the next twelve months.
Headline financials
Revenue & EPS history
Prelude Therapeutics · Revenue · Quarterly
$5.7M
Forward guidance
No quantitative financial guidance provided; clinical timelines noted for PRT13722 and PRT12396.
Tailwinds
- IND clearance received for PRT12396 (JAK2 V617F) with Phase 1 ongoing
- Preclinical data presented for PRT13722 (KAT6A) with Phase 1 expected Q4 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+5.5%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+5.1%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+37.0%
Q4 2023
Best reaction
-8.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -3.1% | -6.7% | -14.2% | |
| Q4 2025 | +5.8% | -6.7% | +13.3% | |
| Q3 2025 | +10.7% | +22.2% | +26.7% | |
| Q1 2025 | -4.1% | -2.5% | +2.5% | |
| Q4 2024 | +4.1% | +1.7% | +14.4% | |
| Q3 2024 | -1.6% | -7.8% | -26.0% | |
| Q2 2024 | +21.6% | +2.2% | -2.0% | |
| Q1 2024 | -6.3% | -2.6% | -1.3% | |
| Q4 2023 | +37.0% | +23.1% | +40.2% | |
| Q3 2023 | +30.8% | +74.6% | +90.8% | |
| Q2 2023 | -2.1% | -4.8% | -2.4% | |
| Q1 2023 | -3.8% | +3.4% | -12.3% | |
| Q4 2022 | +9.2% | +12.0% | +35.1% | |
| Q3 2022 | -8.2% | -12.5% | -38.8% | |
| Q2 2022 | +21.7% | +32.4% | +21.2% | |
| Q1 2022 | +1.0% | +15.5% | +22.0% | |
| Q4 2021 | +16.9% | +3.1% | -16.4% | |
| Q3 2021 | -5.4% | -6.5% | -17.7% | |
| Q2 2021 | -5.3% | -5.7% | -3.4% | |
| Q1 2021 | +8.8% | +3.3% | -21.3% | |
| Q4 2020 | -2.6% | -5.4% | -41.3% | |
| Q3 2020 | -3.4% | +15.3% | +43.4% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro